BARCELONA—Men with intermediate- or high-risk prostate cancer who were treated with low dose rate prostate brachytherapy (LDR-PB) were twice as often cancer-free at five years compared to those given
BARCELONA—Men with intermediate- or high-risk prostate cancer who were treated with low dose rate prostate brachytherapy (LDR-PB) were twice as often cancer-free at five years compared to those given dose-escalated external beam radiation therapy. That’s the finding of the multi-center randomized controlled ASCENDE-RT* trial—the first and so far only study to compare LDR-PB with any other method of radiation delivery. William James Morris MD, a clinical professor at the Vancouver Cancer Centre, Canada, presented data to the ESTRO 2015 Forum and spoke to Oncology Times reporter Sarah Maxwell.